These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1998596)

  • 21. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
    Klingemann HG; Eaves CJ; Barnett MJ; Eaves AC; Hogge DE; Nantel SH; Reece E; Shepherd JD; Sutherland HJ; Phillips GL
    Bone Marrow Transplant; 1994 Sep; 14(3):389-96. PubMed ID: 7994260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5.
    Touw I; Donath J; Pouwels K; van Buitenen C; Schipper P; Santini V; Hagemeijer A; Löwenberg B; Delwel R
    Leukemia; 1991 Aug; 5(8):687-92. PubMed ID: 1715959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
    Sievers EL; Lange BJ; Buckley JD; Smith FO; Wells DA; Daigneault-Creech CA; Shults KE; Bernstein ID; Loken MR
    J Natl Cancer Inst; 1996 Oct; 88(20):1483-8. PubMed ID: 8841024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
    Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
    Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity.
    Lo Coco F; De Rossi G; Pasqualetti D; Lopez M; Diverio D; Latagliata R; Fenu S; Mandelli F
    Br J Haematol; 1989 Dec; 73(4):480-5. PubMed ID: 2482063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse.
    Maraninchi D; Blaise D; Viens P; Brandely M; Olive D; Lopez M; Sainty D; Marit G; Stoppa AM; Reiffers J
    Blood; 1991 Nov; 78(9):2182-7. PubMed ID: 1932739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors.
    Kobayashi K; Kami M; Murashige N; Kusumi E; Kishi Y; Hamaki T; Hori A; Matsumura T; Yuji K; Masuo S; Mori S; Miyakoshi S; Tanosaki R; Mitamura T; Takaue Y; Taniguchi S;
    Br J Haematol; 2005 Jun; 129(6):795-802. PubMed ID: 15953007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Induction of Fc receptors and proliferative effect of recombinant human interleukins 1 and 2 (rhIL-1 and rhIL-2) on the leukemic lines WR19M.1 and WEHI3BD-].
    Mendoza JF; López R; Weiss-Steider B
    Sangre (Barc); 1991 Jun; 36(3):205-9. PubMed ID: 1948540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-2 and myelopoiesis: IL-2 induces blast cell proliferation in some cases of acute myeloid leukaemia.
    Carron JA; Cawley JC
    Br J Haematol; 1989 Oct; 73(2):168-72. PubMed ID: 2684257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy.
    Orleans-Lindsay JK; Deru A; Craig JI; Prentice HG; Lowdell MW
    Clin Exp Immunol; 2003 Sep; 133(3):467-75. PubMed ID: 12930376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics.
    Childs CC; Hirsch-Ginsberg C; Walters RS; Andersson BS; Reuben J; Trujillo JM; Cork A; Stass SA; Freireich EJ; Zipf TF
    Leukemia; 1989 Nov; 3(11):777-83. PubMed ID: 2811478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
    Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
    J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TCR delta gene rearrangements in acute myeloid leukemia with T-lymphoid antigen expression.
    Schmidt CA; Przybylski G; Seeger K; Siegert W
    Leuk Lymphoma; 1995 Dec; 20(1-2):45-9. PubMed ID: 8750622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
    Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
    Blaise D; Attal M; Pico JL; Reiffers J; Stoppa AM; Bellanger C; Molina L; Nedellec G; Vernant JP; Legros M; Gabus R; Huguet F; Brandely M; Hercend T; Olive D; Maraninchi D
    Leuk Lymphoma; 1997 May; 25(5-6):469-78. PubMed ID: 9250817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards endothelial-cell-directed cancer immunotherapy: in vitro expression of human recombinant cytokine genes by human and mouse primary endothelial cells.
    Ojeifo JO; Su N; Ryan US; Verma UN; Mazumder A; Zwiebel JA
    Cytokines Mol Ther; 1996 Jun; 2(2):89-101. PubMed ID: 9384693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin.
    Foa R; Caretto P; Fierro MT; Bonferroni M; Cardona S; Guarini A; Lista P; Pegoraro L; Mandelli F; Forni G
    Br J Haematol; 1990 May; 75(1):34-40. PubMed ID: 2375921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia.
    Urbano-Ispizua A; Matutes E; Villamor N; Sierra J; Pujades A; Reverter JC; Feliu E; Cervantes F; Vives-Corrons JL; Montserrat E
    Br J Haematol; 1992 Jun; 81(2):178-83. PubMed ID: 1322689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
    Curti A; Pandolfi S; Aluigi M; Isidori A; Alessandrini I; Chiodoni C; Testoni N; Colombo MP; Baccarani M; Lemoli RM
    Exp Hematol; 2005 Dec; 33(12):1521-30. PubMed ID: 16338495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.